Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,264.00
Bid: 11,500.00
Ask: 12,400.00
Change: 0.00 (0.00%)
Spread: 900.00 (7.826%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,264.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London pre-open: FTSE set to edge higher in wake of dovish Fed

Thu, 19th Mar 2015 07:41

The UK's blue chip index is expected to tack on between 13 and 17 points to yesterday's large gains, financial bookmakers said, as traders digest and react to the surprisingly dovish policy statement from the US Federal Reserve overnight.The US central bank opted to omit any reference to being "patient" when starting to tighten interest rates.However, the 17 members of the Federal Open Market Committee nearly halved their median projection for the level of the Fed funds rate at year-end 2015 to 0.625%. Estimates from Fed's rate setters for the following two years were also lowered.Before the meeting some hedge-fund managers had publicly warned the monetary authority should be extremely careful on how it proceeds with this new phase in the interest rate cycle.The communiqué from the Fed and follow-up conference from Chair Janet Yellen saw the euro/dollar register its large intraday gain since 2000, no less. Prompt month Brent crude futures were catapulted 5% higher on the news. The main Wall Street market gauges all closed higher by approximately a full percentage point.Stocks to watchUK clothing retailer Next grew its underlying pretax profit by 12.5% last year as overall sales rose by 7.2%. The company said its share buyback scheme meant that underlying EPS grew by 14.7% and dividends for the full year will increase by 16.3%, to 150p.Electronics components distributor Premier Farnell reported adjusted profits before tax down 3% to reach £74m in 2014 but maintained its full-year dividend payout at 10.4p. That came on the back of a 0.8% fall in full-year revenues to £960.1m. However, the company's operating margins declined by less than forecast by analysts, slipping by 40 basis points, to 9.2%. The analyst consensus was for margins of 9%.AstraZeneca has signed an agreement with Japanese-headquartered company Daiichi Sankyo to jointly commercialise a new drug called Movantik, an oral treatment for opioid-induced constipation in adults with chronic non-cancer pain. No longer labelled a controlled substance by the US Drug Enforcement Administration, its launch has been scheduled to take place early in April 2015.
More News
8 May 2024 19:10

Sector movers: Aerospace and Defence, Pharma pace gains

(Sharecast News) - London's main stock market gauges continued to push higher in the middle of the week, even as investors waited on the Bank of England's policy announcement on the following day.

Read more
8 May 2024 17:46

FTSE 100 hits record high, pound slips ahead of BoE verdict

FTSE 100 up 0.5%, FTSE 250 adds 0.4%

*

Read more
8 May 2024 16:36

London close: Stocks rise further ahead of BoE decision

(Sharecast News) - London's stock markets closed with gains on Wednesday, bolstered by a dip in the value of the pound against both the dollar and the euro.

Read more
8 May 2024 09:44

AstraZeneca says withdraws Covid vaccine "for commercial reasons"

(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemic, citing "commercial reasons" and a surplus of updated jabs.

Read more
8 May 2024 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.